Insurance Restructuring or Co-pay Caps? Testing Nuanced Messages In Charged Pricing Debate
This article was originally published in RPM Report
The drug pricing debate isn’t fun for anyone in the biopharma sector, but it isn’t likely to go away soon. A recent Center for American Progress event highlights the challenges of finding the right message in a sound-bite focused climate – but also the benefits of engaging directly with critics.
You may also be interested in...
“Project Indy” offers a joint manufacturer/payor perspective on how to enable value based pricing. It also sounds like a potential proposal to CMS to volunteer for a pilot project.
Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.
Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.